4-(4-硝基苯)哌嗪-1-羧酸叔丁酯 | 130636-61-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(4-硝基苯)哌嗪-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-(4-nitrobenzyl)piperazine-1-carboxylate
• 英文别名: 1-[(4-nitrophenyl)methyl]-4-tert-butyloxycarbonylpiperazine；1-Boc-4-(4-Nitrobenzyl)piperazine；tert-butyl 4-[(4-nitrophenyl)methyl]piperazine-1-carboxylate
• CAS: 130636-61-2
• 化学式: C₁₆H₂₃N₃O₄
• mdl: MFCD03407491
• 分子量: 321.376
• InChiKey: XWWBHMXIEAVTGS-UHFFFAOYSA-N

物化性质

• 熔点：
  99-100 °C
• 沸点：
  436.5±40.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Nitrobenzyl)piperazine-1-carboxylic acid tert-butyl ester
CAS number: 130636-61-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H23N3O4
Molecular weight: 321.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-硝基苯)哌嗪-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 1-[(4-硝基苯基)甲基]哌嗪
  参考文献：
  名称：

  掺入哌嗪生物甾醇酯的磺胺类药物，作为有效的人碳酸酐酶I，II，IV和IX抑制剂。

  摘要：

  从（R）4-（3,4-二苄基哌嗪-1-羰基）苯磺酰胺9a的分子简化开始，这种化合物具有对人碳酸酐酶（hCA）IV的选择性，是一系列带有4的哌嗪和4-氨基哌啶-氨磺酰基苯甲酰胺部分作为Zn结合基团已设计并在人同工型hCA I，II，IV和IX上进行了测试，并使用了停止流动的CO 2水合酶测定。这项工作的目的是推导可用于设计同工型选择性化合物的结构-活性关系。这些结构修饰将类似物的选择性谱从hCA IV更改为hCA I和II，并提高了效能。几种新化合物对hCA II表现出亚纳摩尔活性。配体-hCAII配合物的X射线晶体学用于比较新哌嗪与先前合成的2-苄基-哌嗪类似物的结合模式，从而解释了抑制曲线。

  DOI：

  10.1016/j.bioorg.2019.103130
• 作为产物：
  描述：

  对硝基溴化苄 、 N-Boc-哌嗪 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以90.2%的产率得到4-(4-硝基苯)哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  利用非核苷类逆转录酶抑制剂（NNRTI）结合口袋的耐受区I。第2部分：发现具有高Fsp 3值和良好药物样特性的有效HIV-1 NNRTIs二芳基嘧啶衍生物

  摘要：

  为了产生具有良好的药物样性质的有效的HIV-1非核苷逆转录酶抑制剂（NNRTIs），设计，合成和生物学评估了一系列靶向NNRTI结合口袋的I区的新型二芳基嘧啶衍生物。活性最高的抑制剂10c对大多数病毒板均表现出出色的抗病毒活性，约为2倍（野生型，EC 50 = 0.0021μM），1.7倍（K103N，EC 50 = 0.0019μM），并且效力更强（E138K，EC 50 = 0.0075μM ）比NNRTI药物依曲韦林（ETR）高。此外，赋予10c较低的细胞毒性（CC 50 = 18.52μM）。更重要的是10c与ETR相比，Fsp 3具有改善的类药物特性，且Fsp 3（sp 3碳原子的分数）值增加。此外，进行了分子动力学模拟和分子对接研究以揭示10c在结合口袋中的结合模式。两者合计，10c是有前途的铅化合物，值得进一步研究。

  DOI：

  10.1016/j.ejmech.2020.113051

文献信息

• Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
  申请人：Mutahi W. Mwangi

  公开号：US20070167435A1

  公开（公告）日：2007-07-19

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR 5 )—, —C(N—OR 5 )—CH(R 6 )—, —CH(R 6 )—C(N—OR 5 )—, —O—, —OCH 2 —, —CH 2 O— or —S(O) 0-2 —; Y is —O—, —(CH 2 ) 2 —, —C(═O)—, —C(═NOR 7 )— or —SO 0-2 —; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R 1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R 2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐或溶剂，其中：M为CH或N；U和W分别为CH，或者U和W中的一个为CH，另一个为N；X为键，烷基，—C(O)—，—C(N—OR5)—，—C(N—OR5)—CH(R6)—，—CH(R6)—C(N—OR5)—，—O—，—OCH2—，—CH2O—或—S(O)0-2—；Y为—O—，—(CH2)2—，—C(═O)—，—C(═NOR7)—或—SO0-2—；Z为键，可选择地取代的烷基或被杂原子或杂环基中断的烷基；R1为可选择地取代的烷基，环烷基，芳基，芳基烷基，杂芳基，杂环烷基或苯并咪唑基或其衍生物；R2为可选择地取代的烷基，烯基，芳基，芳基烷基，杂芳基，杂芳基烷基，环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂联合使用，治疗由过敏引起的气道反应、充血、糖尿病、肥胖症、与肥胖有关的疾病、代谢综合征和认知缺陷障碍的组合物和方法。
• [EN] FAK INHIBITORS<br/>[FR] INHIBITEURS DE FAK
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2012110773A1

  公开（公告）日：2012-08-23

  A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

  公式(I)的化合物：其中R1或R2是环胺基团，R5是含有羰基的芳香族基团，用作FAK抑制剂。
• [EN] FAK AND FLT3 INHIBITORS<br/>[FR] INHIBITEURS DE FAK ET FLT3
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014027199A1

  公开（公告）日：2014-02-20

  The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

  使用公式(I)的化合物：(公式(I))在制备用于治疗急性髓系白血病或通过抑制Flt3、或Flt3和FAK得到改善的疾病的药物中的应用。
• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• [EN] NEW FYN KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES FYN
  申请人：ROTTAPHARM BIOTECH SRL

  公开号：WO2016146220A1

  公开（公告）日：2016-09-22

  The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.

  这项发明涉及到化学式(I)的新选择性FYN激酶抑制剂，含有它们的药物组合物，以及它们在药物治疗疼痛和关节炎，包括骨关节炎和类风湿关节炎中的应用。